Working… Menu

MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D) (Meld-ATG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04509791
Recruitment Status : Recruiting
First Posted : August 12, 2020
Last Update Posted : September 16, 2021
Information provided by (Responsible Party):
Universitaire Ziekenhuizen Leuven

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : May 2023